Hepatitis B and C in Australia Annual Surveillance Report Supplement 2016

This Hepatitis B and C in Australia Annual Surveillance Report Supplement 2016 provides an overview of trends in diagnoses, prevalence, incidence, morbidity, care, testing and prevention of hepatitis B and C viral infections. Hepatitis A, D and E are not included in this report, but information about these infections can be found on the National Notifiable Diseases Surveillance System website.
 
The report is divided into two sections: the first section focuses on hepatitis C, and presents data from a range of sources from 2006 – 2015; within this section there is also a focus on the new direct acting antiviral treatments for hepatitis C infection, which presents data from March to July 2016. The second section focuses on hepatitis B, and also presents data from 2006 – 2015. Diagnosis and care cascades are presented for both hepatitis B and C, and a range of data are used to produce these estimates. Further details on how cascade estimates are generated can be found in the Methodological Notes.
 
The Supplement was produced to coincide with the 2016 Australasian Viral Hepatitis Conference and to provide a timely update on the roll out of hepatitis C direct acting antiviral treatments in Australia. With the World Health Organization calling for the elimination of hepatitis B and C by 2030, this report provides vital information on progress and gaps in the Australian response.

Hepatitis B and C in Australia Annual Surveillance Report Supplement 2016

This Hepatitis B and C in Australia Annual Surveillance Report Supplement 2016 provides an overview of trends in diagnoses, prevalence, incidence, morbidity, care, testing and prevention of hepatitis B and C viral infections. Hepatitis A, D and E are not included in this report, but information about these infections can be found on the National Notifiable Diseases Surveillance System website.
 
The report is divided into two sections: the first section focuses on hepatitis C, and presents data from a range of sources from 2006 – 2015; within this section there is also a focus on the new direct acting antiviral treatments for hepatitis C infection, which presents data from March to July 2016. The second section focuses on hepatitis B, and also presents data from 2006 – 2015. Diagnosis and care cascades are presented for both hepatitis B and C, and a range of data are used to produce these estimates. Further details on how cascade estimates are generated can be found in the Methodological Notes.
 
The Supplement was produced to coincide with the 2016 Australasian Viral Hepatitis Conference and to provide a timely update on the roll out of hepatitis C direct acting antiviral treatments in Australia. With the World Health Organization calling for the elimination of hepatitis B and C by 2030, this report provides vital information on progress and gaps in the Australian response.
Year Published
2016
Date Published:
Wednesday, 28 September 2016